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Abstract: In the DELIVER (Full project title: Design of effective and sustainable control strategies for liver fluke in Europe) project
the objective was to analyze 3 recombinant antigens for their capacity to induce a satisfied immune response in sheep, to challenge
the animals with metacercariae of Fasciola hepatica, and to observe their immune response and protection from the parasitosis.
The animals were treated initially with metacercariae and every second week blood was taken for liver enzyme estimation of lactate
dehydrogenase (LDH), gamma-glutamyl transferase (γGT), and antibody response. After the 3rd month of infection all the animals
developed parasitosis, although to different extents. Differential observations of the blood showed a rise in eosinophils after the 3rd
month (typical by parasitoses) and specific reactions of the other white blood cells. The LDH and γGT liver enzymes showed a slight
fluctuation in comparison with the initial values. The antibody (immunoglobulin G1) formations against the different antigens (made
by enzyme-linked immunosorbent assay) were typical as well, but not strong enough to protect the animals from the disease. The
immune response was mostly pronounced against the cathepsin L1 antigen, with the highest values after 5–6 months. It turned out that
the chosen adjuvant was successful too, because of the high response to it alone. The differential count of the blood cells showed a rise
in the eosinophils. The liver enzymes were not typical for this disease. The results gave strong suggestions of how to operate further and
what kind of corrections should be made.
Key words: Fasciola hepatica, TPx and CL1 antibodies, blood smears, LDH, γGT

1. Introduction
There is no doubt about the great importance of finding a
vaccine to combat Fasciola hepatica parasitosis. Much effort
has been invested in this direction but without achieving
great success. The aim of the DELIVER (Full project title:
Design of effective and sustainable control strategies for
liver fluke in Europe) project was to try new recombinant
antigens during this infection in sheep, cattle, and goats
(in Bulgaria, lambs) and to measure some parameters
in the living organism. Presented are the hematological,
biochemical, and immunological examinations of lambs
infected with F. hepatica as well as in control groups, so as
to estimate the impact of these new antigens in preventing
animals from contracting this disease.
2. Materials and methods
2.1. Experimental design
Experimental animals (male sheep < 5 months old, i.e.
lambs) were immunized with recombinant F. hepatica
cathepsin L1 (CL1), recombinant F. hepatica thioredoxin
peroxidase (TPx), recombinant Schistosoma mansoni
(fatty acid binding protein-(FABP) Sm14), or with a
* Correspondence: dianaw33@hotmail.com

combination of the 3. Each of the agents was mixed with an
adjuvant and injected subcutaneously; one control group
(first control) received only the adjuvant (Quil A adjuvant,
1 mL, supplied by Dr JP Dalton, University of Technology
Sydney, Australia) and a second control group (double
control) was not treated at all. At week 10 after the last
immunization (2 occasional immunizations in 1 month)
the animals received viable F. hepatica metacercariae. Blood
samples had been taken from all animals at weeks 1, 4, 6, 8,
10, 12, 14, 16, 18, 20, and 22 and a part of them was stored
for antibody analysis; once monthly the samples were used
for total and differential cell counts, and simultaneously
both liver enzymes lactate dehydrogenase (LDH) and
gamma-glutamyl transferase (γGT) were measured. Fecal
samples from each animal were taken at weeks 18, 20, and
21 for presence of F. hepatica eggs. At the 22nd week the
animals were killed. The fecal testing and morphological
examinations were the subject of another publication and
will not be discussed here.
2.2. Animals
Male, 5 month old Bulgarian Marishka lambs (7 in each
group) were used, sourced from fluke-free areas and
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were verified as being free of any infection by serology,
fecal examination, and liver enzyme assays. The lambs
were housed indoors under controlled conditions for the
duration of the trial.
2.3. Antigens
CL1 and TPx were supplied by Dr JP Dalton (University
of Technology Sydney, Australia) under sub-contract.
FABP (Sm-14) was supplied by Dr M Tendler (Head of
the Laboratory of Eco-epidemiology and Control of
Schistosomiasis and Soil-transmitted Helminthiases,
Oswaldo Cruz Institute, Rio de Janeiro, Brazil).
2.4. Immunizations
Each animal was immunized on 2 occasions (week 1 and
week 4 after the start of the study) with 100 μg of each
recombinant antigen in 1 mL of adjuvant Quil A. The first
control group received the adjuvant alone. The second
control group received only the antigens and was not
challenged. The animals were inoculated subcutaneously
in the neck region.
2.5. Challenge
Each animal from the experimental groups was challenged
with 200 viable F. hepatica metacercariae within a gelatin
bolus, which were administered by a dosing gun 10 weeks
after the last immunization (i.e. 14 weeks after the start of
the study).
2.6. Antibody estimations by enzyme-linked
immunosorbent assay
The standard Liverpool School of Tropical Medicine
(LSTM) enzyme-linked immunosorbent assay (ELISA)
technique of Salimi-Bejestani et al. (1) was used.
The blood samples were centrifuged at 3000 × g/min
without an anticoagulant and the sera were used for the
immunoglobulin G1 (IgG1) estimation. The FABP antigen
lost its protein properties during storage and could not be
used further in the ELISA estimations.
2.7. Sampling
Blood samples (in 2 options for plasma: with anticoagulant
and for sera, or without anticoagulant) were taken from
each animal every second week after the challenge and kept
for antibody analysis, liver enzyme analysis, erythrocyte,
and lymphocyte numbers in the blood (number per liter,
manually counted in Burker chambers) were taken into
consideration after the 8th week.
Blood smears were made for differential cell counts:
eosinophils, neutrophils, basophils, and monocytes (as an
absolute number).
2.8. Grouping
Group I: animals immunized with CL1
Group II: immunized with TPx
Group III: immunized with FABP
Group IV: immunized with all 3 antigens
Group V: immunized with the antigens and without the
adjuvant
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Group VI: immunized with the adjuvant alone
Group VII: not treated at all
Blood samples were taken from the animals before
starting the trial for the purpose of keeping them as double
negative controls for all other investigations (group VII).
2.9. Liver enzyme estimations
LDH and γGT were measured in the time periods
mentioned above (Anthos Labtec Instruments, UK).
2.10. Statistical analyses
With the help of the computer statistical program “Origin,”
results from the ELISA were tested for standard deviations
and standard errors and simultaneously used to calculate
the end point titer using the formula {[x2 – x1) × (1.5 –
y1)] / [y2 – y1]} where:
x1 = 1st dilution
y1 = 1st OD (optical density, 450
nm) (above 1.5)
x2 = 2nd dilution y2 = 2nd OD (above 1.5)
The calculations with “Origin” were employed for the
estimation of the real antibody formations.
2.11. Ethical aspects
The experimental procedures were conducted according
to the Veterinary Medical Office in Bulgaria, which follows
the National Institutes of Health guidelines of care and
use of laboratory animals (Permission with registration
No. BG 1113–007, valid to 2012). The experiments with
animals cannot be replaced with experiments in vitro
because the disease can develop only in living animals.
3. Results
3.1 Antibody responses
The antibody response (IgG) in the experimental
(immunized and infected) and control animals (from
all control groups) was followed once monthly, and the
first measurement was made at the 1st month after the
immunizations.
The CL1-IgG1 graph in CL1-treated sheep starts with
comparatively high levels immediately after the challenge
(Figure 1 a) and around the 8th week the antibodies
reached maximum levels and remained there until the
end of the observation. This already gave an indication
that the disease had shown signs of development. We also
tested the IgG-response in the lambs injected with the
adjuvant and challenged (first controls). The IgG response
in the adjuvant treated and challenged animals (Figure
2a) increased earlier than it did in the CL1-treated and
challenged animals (although not high), but after the 6th
week remained at almost the same value. This showed that
the adjuvant itself gave a rather good expressed antibody
answer and therefore it might be very appropriate in
these experiments as an additive immune inducer. After
the calculations by “Origin” (Figures 1c, 1d, 1g, 1h, 1k,
1i, 1o, and 1p) it turned out that the animals treated only
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Figure 1 (a–p). Immune response to CL1-antigen (with or without adjuvant) – calculations (“Origin”) of SD and SE during the
different weeks postinfection.
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Figure 1. (continued).
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Figure 1. (continued).

with the adjuvant showed a very high degree of anti-CL1response. Two weeks after the infection this response
was twice as high as the response to the CL1-injected
lambs (OD around 0.6 to 0.3 respectively). During the
6th week (Figures 1e and 1f) the response fell to 0.25 in
the adjuvant treated animals, but the values in the OD of
the CL1-treated remained the same. Up to the 12th week
(end of the trial) the responses in the 8th and 12th weeks
remained equal in both cases. The response to TPx was
different in the comparison to that of the adjuvant treated
animals (Figure 2b), which was strong at the beginning
and fluctuating after that with a maximum at the 8th week
and decreasing with fluctuations again up to the end of
the trial. The statistical analysis of the IgG response as
standard deviation and standard errors are given for 2, 6,
8, and 12 weeks after injections and calculated by the given
formula and by use of “Origin” (Figures 1a–1p). Two weeks
after immunization the CL1-IgG1s had a higher SD. The

SE was within normal boundaries. The adjuvant controls
gave higher values (almost twice as high), but the SD was
significantly increased as well. It should be noted that all
animal groups reacted to the mixture of the 3 antigens
in different ways. After the 6th week the CL1-antibodies
dropped down slowly, but did not disappear. The adjuvant
controls remained with a higher response even after the
last (12th) week of the trial (Figures 1o and 1p).
3.2. Liver enzymes
γ-GT was measured before any treatment (first measure,
Figure 3, negative control) and each 2nd week after the
challenge with the metacercariae. The γ-GT showed 2 slight
peaks during the trial, but no special feature was observed.
The change in the levels of this enzyme was not indicative
of the development of parasitosis. LDH values are given in
Figure 4 after 10 measurements for each enzyme. The LDH
decreased slowly up to the end of the trial in all the animal
groups treated with the different antigens.
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3.3 Hematology
During the whole period of the trial the differential blood
estimation showed that up to the 2nd month after giving
the metacercariae (3rd month after the immunizations)
the eosinophils were rising in 4 of the groups (Figure 5).
Only in the group injected with CL1 did this rise reach
very high values during the 5th month and then it dropped
down sharply. The control group (group VI) was taken
into account in the comparison.
The neutrophil number exhibited its own increase
(as shown in Figure 6), but a special conformity for these
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number of measurments

Figure 4. LDH values in the plasma of animals treated with
different antigens.

TPx response 2, 6, 8, and 12 weeks after
infection

3.5
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Figure 3. Liver enzyme γ-GT in the plasma of animals treated
with different antigens.
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cells during the trial was not observed. Their numbers
resembled those of the eosinophils, but with lower values
and a special high value in the 5th month for the 1st group.
The number of basophils increased in the 3rd month
after the immunizations in the 4th group (treated with the
combination of the 3 antigens) (Figure 7). A remarkable
rise in the group of adjuvant-treated animals is seen in
the 4th month and the highest peak against CL1 is again
observed in the 5th month.
The monocytes increased very slowly and a high peak
only appeared in the CL1 group in the 5th month and at
the end of the trial, when the number of these cells was
higher in all groups, their number was quite different in
the group of the 3 antigens (Figure 8).
The total leukocyte number (in 1 L) increased during
the months 3, 4, and 5 up to 10/L after treating with the
mixture of the 3 antigens, followed by the animals treated
with FABB.
Only during the last 3 months of the experiment was a
slight erythrocytosis recorded, but it can be regarded as
negligible.
4. Discussion
These experiments were carried out in the framework of
the DELIVERY project and the results should reflect the
real situation by using these recombinant antigens. We are
obliged to mention that this was not an easy task, because
the parasite F. hepatica has several steps in its life and it
is possible that the immunological answer is not adequate
for all the examined phases in the parasite organism.
The peptide CL1 was isolated by Cornelissen (2) with
the aim of detecting antibodies against F. hepatica and to use
it in immunodiagnostics. It turned out that the occurrence
of common antigens in many helminths remained the
main source of the lack of specificity. The authors therefore
synthesized species-specific epitopes within CL1 that were
specific for F. hepatica and demonstrated greater specificity,
especially during the first weeks of the fasciolosis.
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different antigens.

It has been proposed that the secreted cathepsin Ls
may be involved in the suppression and/or modulation
of Th1 immune responses and induction of nonprotective
host Th2 responses. An analysis by Dalton et al. (3) of
cytokine production by antigen-stimulated spleen cells
of F. hepatica (adult worms CL1-protease) from infected
mice showed that these are predominantly of the Th2 type,
i.e. there is production of interleukin IL-4, IL-5, and IL-10,
but little or no IFN-γ.
Mulcahy et al. (4) mentioned that the vaccines appeared
to target the early migratory stages of the parasite and thus
prevented liver damage to the host. In our case the results
from the cell differentiation examinations, liver enzyme
observations, etc. showed exactly this phenomenon,
which will be discussed below. On the other hand, the
lack of resistance in sheep has been contrasted to the
high resistance in cattle to acute fasciolosis and has led
to a general assumption that cattle, but not sheep, have
the immunological capability of eliminating liver fluke
infections (4).
Harmsen et al. (5) reported some studies on the
proenzyme forms of CL and their properties. Vaccinations
of rats with these forms showed 64%–76% reduction in
fluke load. The authors drew the conclusion that their use
might be helpful in a multisubunit vaccine.
In our experiments, more calculations and remodeling
were done with the CL1 antigen. The response to CL1
increased quite quickly (the maximal OD is observed

1st
month
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3rd
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month month
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6th
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Figure 6. Absolute neutrophil number of animals treated with
different antigens.

between the 6th and 8th week) and afterwards decreased
somewhat and then remained at 1 level (Figure 10 after the
“Origin” calculations). This is indicative that this antigen
induced a prolonged and more stable IgG1 immune
response although not high enough. These results coincide
with those published by Dalton et al. (3), who reported this
period after 4–5 weeks. Bossaert et al. (6) used a somatic
F. hepatica antigen and an adult F. hepatica ES antigen and
infected calves 4 months after immunization with them.
They stated that the mean IgG1 titers were significantly
higher in the single-dose infected group than in the trickle
infected group during the early migratory phase of the
infection. IgG2 values were lower than those of IgG1.
Phiri et al. (7) carried out experiments similar to our
own with sheep treated with 2 kinds of F. hepatica ES and
measured the levels of antibody responses after challenge
with the parasite. They found IgG1 increases around the
2nd week after challenge, which is in full agreement with
our own observations (Figures 1a–1p) after transformation
of the expected values by “Origin”. It is remarkable that the
IgG1 levels in their experiments fluctuated strongly on a
week to week basis as was the case in our studies too. The
pronounced IgG-answer against CL1 in our experiments is
indicative for further success of the present work; there is
a possibility to achieve protection after changing some of
the parameters in the trial.
The calculations gave us the opportunity to compare
the IgG1 profiles at the same dilutions. This part of the
investigation was not entirely satisfactory because the
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Figure 7. Absolute basophil number of animals treated with
different antigens.

immunological responses were not strong enough. The
poor IgG1 response in all treated groups is well explained
in the work by Wolstenholme et al. (8), who discussed in
great detail the resistance of the organism to a variety of
parasites, the parasite genetics, and biology and the use
of antihelminthic compounds. The authors came to the
conclusion that further detailed research is needed to
discover the strategy for effective treatment. This was why
the goal of our project was to investigate all circumstances
necessary for achieving positive results against F. hepatica
as well.
The IgG1 responses in the adjuvant Quil A-treated
animals remained comparatively high. Figure 2a and
Figures 1c, 1d, 1g, 1h, 1k, 1i, 1o, and 1p show that these
responses are even higher at the start of the trial, and after
falling in the 8th week they remained equal to the CL1response at the end of the observation. This adjuvant,
initially refined by Dalsgaard (9) and containing triterpene
glycosides, was estimated by Kensil et al. (10) and has
subsequently been subjected to intensive investigations. Its
efficacy was followed in lambs with F. hepatica parasitosis
by Haçarız et al. (11), who established a maximum
response during the 8–10-week period after a sharp
start. Our observations in this respect generally coincide
with those of these authors, but the maximum value is
somewhat earlier than 6–8 weeks.
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Figure 8. Absolute monocyte number of animals treated with
different antigens.

The fact that the antibody response to the adjuvant
alone was stimulated to a great extent shows that
the adjuvant was well chosen. Haçarız et al. (11) was
investigating 3 adjuvants and came to the conclusion
that the Quil A adjuvant could be useful in anti-Fasciola
hepatica vaccines, because it induces a strong elevation
of the immune response after such an infection. It can be
seen in Figures 1c and 1d of our results that in the same
week after challenge (2nd week) the response to CL1 in
adjuvant-treated animals is even higher than that in the
group without the adjuvant.
The additive effect after the simultaneous application
of the 3 antigens (group IV) is not surprising, because
each separate antigen gave its own positive response and
this was completed by the adjuvant. Donnelly et al. (12)
made a recombinant antioxidant thioredoxin peroxidase
(TPx) (bearing in mind that it is present in the F. hepatica
parasite excretory-secretory/ES/products) and showed
that TPx not only increases the number of peritoneal
macrophages, but directly converts them to RAW 264.7
phenotype, characterized by production of high levels
of IL-10, prostaglandin E2. In our experiment animals
treated with TPx (group II) showed a better increase in
the monocytes only during the 3rd and 6th months. In
Figures 1a–1p and 2 one can see that in almost every case
the application of the 3 antigens simultaneously leads to
an increase in the immunocompetent cells (eosinophils,
monocytes, etc).
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The liver enzymes (LDH and γGT) had their own
shape in these experiments. Their values in our trial are
different; the γGT rose only between the 8th and 9th weeks
and the LDH values fell continuously until the end of the
trial (not characteristic for liver damage). During the
same parasitosis Haçarız et al. (11) established an increase
in this enzyme between the 13th and 23rd weeks, with a
maximum in the 19th week, which is different from our
data (Figure 4). The activity of γGT in the adjuvant-treated
animals in our experiments did not change too much in
comparison to the value of the controls (Figure 3, the first
measurement with an exception in the 2nd measurement),
but this evaluation cannot be explained by an adoptive or
antiparasitic reaction. The values of γGT are not as high as
in the experiment reported by Bossaert et al. (6). According
to them, the immunization with 2 different F. hepatica
ES-proteins 4 months prior to infection of calves with F.
hepatica led to mean serum levels of LDH and γGT around
12–14 weeks after primary infection. Their activities were
higher in the single-dose infected groups but only around
the peak values. They did not find a correlation between
the fluke number and antibody titers and suggested that
IgG1 production has little protective effect against F.
hepatica infection. It is possible that the antigen used,
CL1, prevented the liver damage, but not the infection of
sheep. Yang et al. (13) estimated the values of LDH and
γGT after fluke infection and stated that plasma LDH was
significantly elevated from 6 to 21 weeks postinfection.
Significant increases in plasma γGT occurred from 8 to 26
weeks postinfection, reaching maximum values at the 15th
week. They were working with other animals, and so their
results are different from ours.
The LDH values in all experimental groups had the
same shape and the highest values were observed during
the first week of the parasitosis. The lambs injected with
the adjuvant did not show different features, which was
not the case in the experiments conducted by Haçarız et al.
(11), who established a maximal increase in this enzyme
during the 13th week.
The results concerning the differential blood count are
in agreement with the work by Pulendran and Ahmed (14),
who pointed out that the helminths induce differentiation
of Th2 cells, whose cytokines (IL-4, IL-5, and IL-10)
induce IgE and eosinophil mediated destruction of the
pathogens. Serradell et al. (15) performed experiments
showing eosinophil apoptosis during F. hepatica infection
in rats and concluded that diminution in Eo survival in
early infection could be a parasite strategy in order to
prevent a host immune response. Unfortunately, they did
not present any data about the changed eosinophil levels
in the blood during different periods of the parasitosis.
As seen from our Figure 5, the levels of the eosinophils
increased in the experimental animals (independent from

the injected antigen) between the 3rd and 4th months
after infection, but a high peak only in the CL10 group
appeared in the 5th month. Subsequently, a decrease was
noticed—the question is why? The answer might be found
in the work of Serradell et al. (15) and it would be worth
following up. The eosinophil’s number is unstable in our
experiments although it increased after the 3rd month.
It should be noted that the eosinophils in the adjuvanttreated examples remained at higher and almost equal
values up to the 6th (last) month (Figure 5). Whether
this happens because of some protective effect should be
examined.
Zhang et al. (16) presented some data about the
cellular response in sheep, only they infected the animals
with 2 kinds of parasite, Fasciola hepatica and Fasciola
gigantica, and ascribed the answer to parasitic excretorysecretory products (ESPs). Eosinophil numbers in their
experiments increased more quickly and strongly in
F. gigantica-infected sheep than in F. hepatica-infected
ones. In both groups, peripheral blood mononuclear cell
(PBMC) proliferation in response to the ESPs showed
similar kinetics. The kinetics of the eosinophil count in
their examinations was biphasic with peaks at the 4th week
postinfection (WPI) and 9–10 WPI for the group with F.
hepatica and the 4th WPI and 11–13 WPI for the group
with F. gigantica. The second peak of the eosinophil count
for the group with F. hepatica coincides completely with
our investigations and the decrease in this count after this
maximum peak is the same. These authors give data about
the count of other cells; the PBMC received a proliferation
of these cells during the first 8 weeks postinfection with F.
hepatica. In our experiments the mononuclears increased
slowly with an exception during the 5th month in CL1 and
during the 6th month in Ag-combination–treated animals
(Figure 8). Furthermore, we studied the number of the
neutrophils (Figure 6) and basophils (Figure 7) during the
parasitosis with the different antigens. The neutrophils did
not show a specific response, but again increased in the 5th
month among the CL1-group. In contrast, the basophils
remarkably only increased in the 3rd month postinfection
in antigen-mixture treated animals; during the 4th month
an increase in the same cells was observed in the adjuvant
group and during the 5th month in the CL1-group (Figure
7). For now we cannot give any reasonable explanation for
this phenomenon.
The use of new F. hepatica antigens with the aim
of reaching some protection from this parasitosis gave
discrepant results. The immune response was mostly
pronounced against CL1, with highest values after 5–6
months, but with the decrease thereafter we could not
achieve full protection results. It turned out that the
chosen adjuvant is very successful because the animals
reacted to it with a comparatively high response. The
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differential count of the blood cells did not show any
special features; the eosinophils rose very significantly in
each group after the initial 3–4 months and showed in
this way that development of the parasitosis had already
started. Nevertheless, the liver enzymes were not typical
for this disease.
Our conclusion after finishing the trials of the project
is that several aspects have to be changed to achieve

successful results. As we assumed, it might be useful to
try performing the same experiments in all the directions,
firstly in small animals, and to take all the above mentioned
untried ideas into account. Secondly, it would be good to
think about a 2-step vaccine (antigens), which might be
different in each period of the examinations.
The problem is of great importance especially for farms
and the expectations are even greater.
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